Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07288307

Surgical Evacuation Versus Methotrexate Injection in Treatment of Caesarean Scar Pregnancy [Clinical Trial ]

The aim of the study is to compare the effectiveness and the complications of Ultrasound guided surgical evacuation versus using combined local and systemic methotrexate injection for management of caesarean scar pregnancy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Caesarean Scar Pregnancy

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Gestation age Less than 12 weeks. Hemodynamically stable patient with un ruptured CSP. Non disturbed scar pregnancy . Acceptance of possible prolonged follow up, repeated HCG tests, the need for additional treatment doses and possible bleeding and subsequent hysterectomy.

-

Exclusion criteria

  • Patient refuse TOP. Gestation age More than 12 weeks . Hemodynamically unstable patient with ruptured CSP. Contraindication for methotrexate as hepatic disorders, renal disorders ,hypersensitivity to the drug and autoimmune diseases.

Treatment and study plan

Surgical evacuation and methotrexate injection

Procedure

Surgical evacuation of the scar pregnancy using ultrasound and local and systemic methotrexate injection

Primary outcomes

  1. Success rate of treatment either by surgical evacuation or by methotrexate injection

    Time frame: Up to 8 weeks post -intervention

    The proportion of participants achieving complete resolution of caesarean scar pregnancy without the need of additional intervention

Secondary outcomes

  1. Bleeding during the procedure

    Time frame: Up to 8 weeks post -intervention

  2. The need for additional intervention

    Time frame: Up to 8 weeks post -intervention

  3. Time for serum-hCG normalisation (days).

    Time frame: Up to 8 weeks post -intervention

  4. Hospital stay (days).

    Time frame: Up to 8 weeks post -intervention

  5. Uterine perforation.

    Time frame: Up to 8 weeks post -intervention

  6. Occurrence of drug complications

    Time frame: Up to 8 weeks post -intervention

Study contacts

Contact information is provided by the study sponsor or research team.

Badr Atef AbdAllah, MD

CONTACT

[email protected]

+201092975253

Sponsors and collaborators

Lead sponsor

Minia University

Other

Registry information

Official study title

Ultrasound Guided Surgical Evacuation Versus Combined Local and Systemic Methotrexate Injection for Management of Caesarean Scar Pregnancy [Clinical Trial ]

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 17, 2025
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.